Please note that the preliminary program will continue to be updated as details are finalized.
Registration for the pre-conference workshop is in addition to meeting registration. The registration fee is $95.
ISBER Update: Qualification in Biorepository Science
Presented by: Brent Schacter
ISBER and the ASCP have partnered to create a new qualification exam for biobankers. This short presentation will provide the audience with updated information about this qualification program in the field of biorepository science.
Basic Business Planning for Biobanking
Presented by: Marianne Henderson, Daniel Simeon-Dubach, Kirstin Goldring
Successful biobanking operations begin with accurate and responsible planning. This session will provide guidance on how to fulfill your biobanks mission by formulating a business plan that will satisfy stakeholders through the use of SMART performance metrics and audit points. Discussions will include infrastructure assessments, funding and cost management, and SWOT analysis.
Success is the Result of Preparation: Emergency Planning for Biobanks
Presented by: Helen Morrin, Rebecca Pugh
Emergencies can occur everywhere and biobanks are just as likely as every other industry to suffer the consequences of poor planning. This session will help you build a culture of preparedness to ensure that your assets (specimens, data, infrastructure, and staff) can be protected from disasters. Discussion will include risk assessment, crisis management, critical response procedures, planning for natural disasters, as well as data protection and recovery. Interactive activities will offer the opportunity to discuss the unique emergencies that may affect your operations and provide solutions to create your successful emergency plans.
Pre-registration required. Registration fee is $5.
Research technologies are transforming our biological knowledge-base in ways that have never been possible. As the stewards of quality biospecimens and associated big data, biobanks are providing pathways to diagnostics and discovery that permeate across the globe with the goal of improvement in prevention, wellness, and healthcare applications. The opening plenary of ISBER 2020 aims to provide high-impact scientific narratives in which biobanks have paved the road towards a better tomorrow. Accomplishments in biomarker discovery, community engagement, and advancements in artificial intelligence will be some of the storylines highlighted by speakers who have utilized biobanks for their research.
KEYNOTE: The Transformative Power of Lifestyle Medicine
Dean Ornish, MD, Preventive Medicine Research Institute, USA
Biodiversity Archives as Databanks of Ecosystems Past
Kyle Van Houtan, PhD, Monterey Bay Aquarium, USA
CIRM and the Translation of Science into Cell and Gene Medicines
Abla Creasey, PhD, Californa Institute for Regenerative Medicine, USA
Making Real Advances in Health and Life Sciences
Lester Russell, MD, MBA, FFCI, National Health Service, United Kindgom
Advancing personalised medicine will require new and effective biomarkers that will aid in early and better diagnosis and the development of efficient new therapies. The hallmark of such advances lies in successful translational research which utilizes human biospecimens. Breakthrough discoveries will therefore require quality biospecimens for the identification, development and validation of new research findings.
The session represents a review of biobanking of novel human cell systems for a new generation of cellular therapies and personalised diagnostic testing. Speakers will address the new challenges that these systems bring for biobanks in terms of ethics, data management, preservation technology, quality control and characterisation. They will also present potential new technologies and thinking that will be needed to meet these challenges.
Biospecimens, Biomarkers, Bio-Signatures and Proteo-Genomics to Profile Human Diseases
Ida Biunno, PhD, ISENET Biobanking, Italy
Creation of the Largest Human iPSC Collection in the World for Disease Modeling and Drug Screening
Stephen Lin, PhD, California Institute for Regenerative Medicine, USA
Blood Profiling Atlas in Cancer (BloodPAC) Consortium: Raising the Bar for LBx Data in Public Databases
Lauren Leiman, MS, MBA, Blood Profiling Atlas in Cancer (BloodPAC), USA
Jerry Lee, PhD,University of Southern California, USA
The European Bank for Induced Pluripotent Stem Cells (EBiSC)
Heiko Zimmermann, PhD, Fraunhofer Institute for Biomedical Engineering, Germany
Biorepository specimens and data can only fulfill their potential to truly transform health and accelerate scientific discovery if the outcomes are robust and meaningful for all. Biobanks need to be inclusive of all populations, including the underserved and vulnerable communities to address the current lack of diversity and genetic bias, in addition to reducing health disparities. The advent of precision medicine and increased use of genomic tools (including WGS, WES, targeted gene panels, somatic sequencing in cancer, etc.) in both clinical medicine and research has highlighted the urgency to acquire samples from diverse genetic populations and ancestral communities to create meaningful results for all groups. Engagement with these communities face additional challenges, requiring sensitive responses to building trust and partnerships, to meet each community’s needs.
This session will highlight the importance of including underserved and vulnerable communities in biobanking and a roadmap to address the missing communities and populations. Presentations will include an overview of the breadth and need in this field and focus on the engagement and proven methods for recruitment and retention of these communities, along with research outcomes and impacts. A panel discussion featuring experts with further global perspectives and experience concludes this session.
Underserved and Vulnerable Population Biobank Participation: Is it happening?
Paula Kim, TRAC-Translating Research Across Communities, USA
Recruiting Racial & Ethnic Minority Women to the Komen Tissue Bank: A Motivational Roadmap
Kathi Ridley-Merriweather, MA, Susan G. Komen Tissue Bank at the IU Simon Cancer Center, USA
Biobanking – A Southern African Perspective
Himladevi Soodyall, PhD, Academy of Science of South Africa, South Africa
Biobanks have become key assets to research and clinical care. Biobanks require financial and operational support from organizations, key stakeholders and the community to be sustained. This plenary symposium will highlight scientific success stories that have resulted from the use of fit for purpose biospecimens and data from biobanks to power their findings and translation into practice. Scientific success feeds back to increase the stature and reputation of biobanks as an important infrastructure in discovery research. Lessons learned from this plenary will be specific examples of how scientific success can be leveraged to increase the value/reputation and financial, operational and social sustainability of biobanks.
KEYNOTE: From Human Tumor Biobanking to Human Tumor 3D-Bioprinting: Innovating for Personalized Medicine in Oncology
Nicolas Forraz, PhD, CTI Biotech, France
The Russian Radiobiological Human Tissue Repository of the Southern Urals Biophysics Institute
Christopher Loffredo, PhD, Georgetown University Medical Center, USA
Reef Coral Health Evaluation and Biobanking in an Era of Changing Global Climate
Anderson Mayfield, PhD, NOAA/University of Miami, USA
Biospecimens are collected because they contain the information we require to understand biology, disease and the world we live in. Biobanks have become the ‘librarians’ essential to unlocking the stories associated with each biospecimen. In vision the next generation of biobank having specimens enriched by clinical, molecular and Omics data, will biobanks need to be run as data-driven enterprises? Should they be active in the generation of vast amounts of computer readable information and its interrogation? How are biobanks preparing for a future where biospecimens are integral to an informatics driven discovery process, engaging with the informatics industries as active partners?
Integrative Analysis of Clinical and Genomic Data Reveals Novel Genes Associated with Cardiovascular Traits
Benjamin Glicksberg, PhD, Icahn School of Medicine at Mount Sinai, USA
Beyond DNA: Extending EHR-Linked Biobanks to Biomarker Discovery
Quinn Wells, MD, PharmD, MSCI, MS, Vanderbilt University Medical Center, USA
Large-Scale Inference Across Genomes and Population Cohorts
Manuel Rivas, PhD, Stanford University, USA
Challenges in Biomaterial Annotation and Data Integration
Michael Neumann, PhD, Interdisciplinary Bank of Biomaterials and Data Würzburg – IBDW, Germany
Biobanks have been portrayed as having the promise to unlock biological processes and promote a better tomorrow. Following the advent of the human genome project, biobanks have become the bedrock to accelerating scientific discoveries. Stemming from the success stories is a blueprint that places the biobank community at the forefront of research infrastructure for many generations to come.
Successful repository operations with a solid base in the implementation of best practices are universal and can be scaled for implementation in any size operation. This session will highlight proven, successful repository operations across the globe. Presentations will demonstrate how repositories stayed relevant and developed coordinated activities to tackle challenges and the changing demands of the scientific communities they serve. Discussions will include utilization of the methods and technology that support acquisition, data annotation, processing, quality control, cryopreservation, and cold-chain logistics.
Navigating and Optimizing Cryopreservation Protocols and Technology through Global Research and Innovations
Dayong Gao, PhD, University of Washington, USA
CNGB’s Approach for Better Sample/Data Sharing
Yunice Shao, MD, MPH, China National GeneBank, China
Shirley Tsang, BioMatrix, USA
Digital Pathology Tools: Enhancing Collection, QA and Research
Rajiv Dhir, MD, MBA, University of Pittsburgh, USA
Evidence-Based Biobanking in the Interface Between Translational Cancer Research and Cancer Diagnosis
Iman Farahat, MD, PhD, Egyptian National Cancer Institute, Egypt